[PRESS RELEASE – New York, United States, December 11th, 2025] TestMachine, the AI-driven blockchain security company safeguarding billions in digital assets, today[PRESS RELEASE – New York, United States, December 11th, 2025] TestMachine, the AI-driven blockchain security company safeguarding billions in digital assets, today

TestMachine Secures Over $6.5M In Venture Funding To Expand AI-driven Blockchain Security Solutions

2025/12/12 17:14
3 min read

[PRESS RELEASE – New York, United States, December 11th, 2025]

TestMachine, the AI-driven blockchain security company safeguarding billions in digital assets, today announced it has raised $6.5 million in venture funding to accelerate the global rollout of its flagship platform, Predator. The round was led by Blockchange Ventures, Decasonic, Delphi Ventures, and New Form Capital. The investment will accelerate the development and deployment of TestMachine’s flagship AI platform, Predator, which is now fully integrated into Coinbase’s token security and deployment process.

Other participants in the round included Baboon, UDHC, Auros Global, Generative Ventures, Contango Digital and Santiago Santos. The funding will support the further development of the Predator high-fidelity simulation capabilities.

TestMachine’s groundbreaking automated security approach has been implemented and trusted by leaders across the digital asset industry. Coinbase has integrated Predator into its CEX and newly launched DEX trading feature, using TestMachine to scan millions of tokens across multiple risk factors on a daily basis. With Predator, it takes just seconds to analyze an asset for risks, faster and deeper than any manual process.

The funding will help TestMachine expand Predator across crypto exchanges, custodians, market makers and DeFi protocols. By simulating real-world attacks before they happen, the platform empowers the industry to stay ahead of threats — delivering stronger, more reliable blockchain infrastructure for the entire ecosystem.

About TestMachine

TestMachine was founded in 2021 with a core mission: to ensure the safety, transparency, and reliability of smart contracts, digital assets, and blockchain infrastructure — empowering a secure and trustworthy decentralized future. TestMachine’s flagship technology, Predator, provide developers, DeFi protocols, traders, and exchanges with an AI-driven, continuous security platform that detects, mitigates, and prevents risk in real time

TestMachine’s Predator leverages AI to dynamically identify and exploit smart contract vulnerabilities. Unlike traditional code audits, it offers a complete view of blockchain assets — from economic risk to software vulnerabilities and semantic behaviors. By combining continuous testing with real-time behavioral analysis, TestMachine delivers the most proactive and adaptive layer of security in Web3.

TestMachine is currently monitoring over 1 million tokens in real time, surfacing an unprecedented volume of real-world risks. From a validation set of 11,000 tokens, the system correctly identified 100% of rug pulls, totaling over $120M in value.

Users can visit www.testmachine.ai for more information and to get started today.

The post TestMachine Secures Over $6.5M In Venture Funding To Expand AI-driven Blockchain Security Solutions appeared first on CryptoPotato.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26